Expansion momentum QPS is actively expanding its footprint with new offices and facilities in Springfield, Massachusetts and Newark, New Jersey, signaling increased capacity and regional reach that can be leveraged to win more clinical development and lab services work from nearby biopharma companies.

Growth and hiring Significant headcount growth including a $16.6M investment and 135 new jobs in Delaware Technology Park indicates ongoing scale-up and capability enhancements, presenting opportunities to upsell end-to-end CRO services and larger project scopes.

Advanced capabilities Investments in LC-MS with 13 instruments across multiple labs and specialized facilities for Leukopak and cell therapy reflect strong analytical and cell therapy execution capabilities, opening doors for clients pursuing bioanalysis, translational medicine, and advanced therapy development.

Strategic partnerships Recent collaboration with Ryght AI to optimize clinical trial processes demonstrates a commitment to integrating cutting-edge tech, suggesting cross-sell potential for process automation, data analytics, and telemetry services to improve study efficiency for sponsors.

Clinical and regulatory strength With GLP/GCP compliance, neuropharmacology, DMPK, toxicology, and translational medicine expertise, QPS presents a compelling value proposition for sponsors seeking high-quality preclinical and clinical development under rigorous regulatory standards, enabling targeted outreach to mid-to-late stage programs.